Curcumin inhibits the classical and the alternate pathways of complement activation

Annals of the New York Academy of Sciences

Volumn 1056, Issue , 2005, Pages 100-112

  Kulkarni, Amod P ^a   Ghebremariam, Yohannes T ^a   Kotwal, Girish J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Alternate pathway (AP); Bb; C3b; Classical pathway (CP); Complement; Curcumin; Hemolysis; Quercetin; Rosmarinic acid; VCP

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENT; CURCUMIN; QUERCETIN; ROSMARINIC ACID; SODIUM HYDROXIDE; TURMERIC; UNCLASSIFIED DRUG; VACCINIA VIRUS COMPLEMENT CONTROL PROTEIN; VIRUS PROTEIN; ZYMOSAN;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; COMPARATIVE STUDY; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ERYTHROCYTE; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; NEUROPROTECTION; SERUM;

CURCUMA LONGA; VACCINIA VIRUS;

EID: 29744460451     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1352.007     Document Type: Conference Paper

References (50)

1. http://www.aarogya.com/Complemcntary/Ayurveda/commonherbs.asp
2. ANNA CAROLINA, C.M.M. et al. 2003. Extraction of essential oil and pigments from Curcuma longa [L.] by steam distillation and extraction with volatile solvents. J. Agric. Food Chem. 51: 6802-6807.
3. JAGETIA, G.C. & G.K. RAJANIKANT. 2004. Role of curcumin, a naturally occurring phenolic compound of turmeric in accelerating the repair of excision wound, in mice whole-body exposed to various doses of γ-radiation. J. Surg. Res. 120: 127-138.
4. GAFNER, S. et al. 2004. Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry 65: 2849-2859.
5. JOBIN, C. et al. 1999. Curcumin blocks cytokine-mediated NF-κB activation and proinflamniatory gene expression by inhibiting inhibitory factor i-kb kinase activity. J. Immunol. 163: 3474-3483.
6. CHUN, K.S. et al. 2003. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis 24: 1515-1524.
7. BANERJEE, M. et al. 2003. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol. Immunotoxicol. 25: 213-224.
8. TAKADA, Y. et al. 2004. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclinD1, and abrogation of tumor cell proliferation. Oncogene 23: 9247-9258.
9. TACNET-DELORME, P. et al. 2001. β-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for Aβ on the C1q globular regions. J. Immunol. 167: 6374-6381.
10. SANDERS, M.E. et al. 1986. Activated terminal complement in cerebrospinal fluid in Guillain-Barre syndrome and multiple sclerosis (abstr). J. Immunol. 136: 4456-4459.
11. SELLEBJERG, F. et al. 1998. Intrathecal activation of the complement system and disability in multiple sclerosis. J. Neurol Sci. 157: 168-174.
12. SEWELL, D.L. et al. 2004. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J. Neuroimmunol. 155: 55-63.
13. ANDERSON, A.J. et al. 2004. Activation of complement pathways after contusion-induced spinal cord injury. J. Neurotrauma 21: 1831-1846.
14. SORURI, A. et al. 2003. Anaphylatoxin C5a induces monocyte recruitment and differentiation into dendritic cells by TNF-alpha and prostaglandin E2-dependent mechanisms. J. Immunol. 171: 2631-2636.
15. TAKANO, T. & A.V. CYBULSKY. 2000. Complement C5b-9-mediated arachidonic acid metabolism in glomerular epithelial cells: role of cyclooxygenase-1 and -2. Am. J. Pathol. 156:2091-2101.
16. FISCHER, W.H., M.A. JAGELS & T.E. HUGLI. 1999. Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a (desArg). J. Immunol. 162: 453-459.
17. MINGHETTI, L. 2004. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J. Neuropathol. Exp. Neurol. 63: 901-910.
18. KOTWAL, G.J. & B. Moss. 1988. Vaccinia virus encodes a secretory polypeptide structurally related to complement control proteins. Nature 335: 176-178.
19. MCKENZIE, R. et al. 1992. Regulation of complement activity by vaccinia virus complement-control protein. J. Infect. Dis. 166: 1245-1250.
20. REYNOLDS, D.N. et al. 2004. Vaccinia virus complement control protein reduces inflammation and improves spinal cord integrity following spinal cord injury. Ann. N.Y. Acad. Sci. 1035: 165-178.
21. HICKS, R.H. et al. 2002. Vaccinia virus complement control protein enhances functional recovery after traumatic brain injury. J. Neurotrauma 19: 705-714.
22. KOTWAL, G.J., D.K. LAHIRI & R. HICKS. 2002. Potential intervention by vaccinia virus complement control protein of the signals contributing to the progression of central nervous system injury to Alzheimer's disease. Ann. N.Y. Acad. Sci. 973: 317-322.
23. SAHU, A., N. RAWAL & M.K. PANGBURN. 1999. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b. Biochem. Pharmacol. 57: 1439-1446.
24. PEAKE, P.W. et al. 1991. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase. Int. J. Immunopharmacol. 13: 853-857.
25. CIMANGA, K. et al. 1995. In vitro anticomplementary activity of constituents from Morinda morindoides. J. Nat. Prod. 58: 372-378.
26. KOTWAL, G.J. et al. Inhibition of the complement cascade by the major secretary protein of vaccinia virus. Science 250: 827-830.
27. AISEN, P. S. et al. 2003. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289: 2819-2826.
28. REINES, S.A. et al. 2004. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66-71.
29. SCHARF, S. et al. 1999. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 53: 197-201.
30. YANG, F. et al. 2005. Curcumin inhibits formation of amyloid (beta) oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 280: 5892-5901.
31. FRAUTSCHY, S.A. et al. 2001. Phenolic anti-inflammatory antioxidant reversal of A beta-induced cognitive deficits and neuropathology. Neurobiol. Aging 22: 993-1005.
32. MUKHOPADHYAY, A. et al. 1982. Anti-inflammatory and irritant activities of curcumin analogues in rats (abstr). Ag. Actions 12: 508-515.
33. KOTWAL, G.J. 1994. Purification of virokines using Ultrafiltration. Am. Biotechnol. Lab. 12: 76-77.
34. http://www.quidel.com
35. PRYZDIAL, E.L. & D.E. ISENMAN. 1986. A reexamination of the role of magnesium in the human alternative pathway of complement. Mol. Immunol. 23: 87-96.
36. CHAINANI-Wu, N.J. 2003. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). Alt. Complement Med. 9: 161-168.
37. MAZZEO, A. et al. 2004. Immunolocalization and activation of transcription factor nuclear factor kappa B in dysimmune neuropathies and familial amyloidotic polyneuropathy (abstr). Arch. Neurol. 61: 1097-1102.
38. MEDVEDEV, A.E. et al. 1998. Involvement of CD14 and complement receptors CR3 and CR4 in Nuclear Factor-κB activation and TNF production induced by lipopolysaccharide and group b streptococcal cell walls. J. Immunol. 160: 4535-4542.
39. O'BARR, S. & N.R. COOPER. 2000. The C5a complement activation peplide increases IL-1b and IL-6 release from amyloid-b primed human monocytes: implications for Alzheimer's disease. J. Neuroimmunol. 109: 87-94.
40. SORURI, A. et al. 2003. Anapliylatoxin C5a induces monocyte recruitment and differentiation into dendritic cells by TNF-α and prostaglandin E2-dependent mechanisms. J. Immunol. 171: 2631-2636.
41. SINGH, S. & B.B. AGGARWAL. 1995. Activation of transcription Factor NF-κB is suppressed by curcumin (diferulolylmethane). J. Biol. Chem. 270: 24995-25000.
42. MURTHY, K.H. et al. 2001. Crystal structure of a complement control protein that regulates both pathways of complement activation and binds heparan sulfate proteoglycans. Cell 104: 301-311.
43. WADE, L.G. 1995. Structure and synthesis of alcohol. In Organic Chemistry. B.M. Cappuccio, Ed.: 402. Prentice Hall, Inc. A Simon & Schuster Company, New Jersey.
44. BUREEVA, S. et al. 2005. Inhibition of classical pathway of complement activation with negative charged derivatives of bisphenol A and bisphenol disulphates. Bioorg. Med. Chcm. 13: 1045-1052.
45. SAHU, A. & M.K. PANGBURN. 1996. Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3. Biochem. Pharmacol. 51: 797-804.
46. TONNESEN, H.H., J. KARLSEN & A. MOSTAD. 1982. Structural studies of curcuminoids. 1. The crystal structure of curcumin. Acta Chem. Scand. B. 36: 475-479.
47. WADE, L.G. 1995. Additions and condensations of enols and enolate ions. In Organic Chemistry. B.M. Cappuccio, Ed.: 1079. Prentice Hall, Inc. A Simon & Schuster Company, New Jersey.
48. MIN, B.S. et al. 2003. Anti-complement activity of constituents from the stem-bark of Juglans mandshurica. Biol. Pharm. Bull. 26: 1042-1044.
49. PIERONI, A. et al. 2000. Studies on anti-complementary activity of extracts and isolated flavones from Ligustrum vulgare and Phillyrea latifolia leaves (Oleaceae). J. Ethnopharmacol. 70: 213-217.
50. KAMINAGA, Y. et al. 2003. Production of unnatural glucosides of curcumin with drastically enhanced water solubility by cell suspension cultures of Catharanthus roseus. FEBS Eett. 555: 311-316.